Claremont, CA (PRWEB) April 29, 2013
Disease causing bacteria shield themselves in wounds from antibiotics by creating protective environments called biofilms. Wound infections that are contaminated with bacterial biofilms lead to delayed healing and increased inflammation. Because of the inability of antibiotics to effectively kill all of the bacteria in the biofilm, these biofilms also help the bacteria to develop multi-drug resistance.
Acinetobacter baumannii, a bacterium that is naturally resistant to most antibiotics, is a particular concern in healthcare settings. Acinetobacter rapidly forms biofilms that are very difficult to treat and are prevalent in hospitals and among soldiers injured in Iraq. More than 3,300 U.S. injured troops have developed Acinetobacter infections in military hospitals. Acinetobacter is also a well-documented civilian hospital pathogen, particularly in ICU and trauma patients. It can live on dry environmental surfaces in an ICU for up to 13 days, and has been recovered from various sites in the patients environment, including bed curtains, bed rails, furniture, and hospital equipment.
Synedgen has developed a new approach to topical treatment of bacterial infections that does not rely on traditional antibiotics or their mechanisms of action. Synedgens novel, non-toxic biopolymer, SY203, clumps bacteria and disrupts adhesion of biofilms to facilitate safe and effective removal from the wound. In animal and in vitro studies, SY203 has been shown to have residual activity to prevent adhesion of bacteria to wound tissue, providing a protective, long-term barrier to colonization. Using this novel treatment, it is not necessary to try to kill all of the bacteria in order to treat the infection. The use of antibiotics with sub-therapeutic killing is the major source of generation of antibiotic resistance.
Topical antiseptics, such as hydrogen peroxide, Sulfamylon